Voyager Therapeutics Inc is functional in the United States biotechnology industry. Its focus lies in the research and development of gene therapies for the cure of severe diseases of the central nervous system such as the Parkinson's, Huntington's and Alzheimer's disease. The company has developed products such as VY-AADC01 for Advanced Parkinson's Disease, VY-HTT01 for Huntington's Disease. Voyager's sole source of revenue is generated through its collaboration with a company called Genzyme. Genzyme funds the collaboration for the multiple gene therapy programs, including programs for Parkinson's disease, Friedreich's ataxia, and Huntington's disease, as well as other CNS disorders.
| Website: | www.voyagertherapeutics.com |
| Email: | mosborne@vygr.com |
| Main Phone: | +1 857 259-5340 |
| Address: | 75 Sidney Street |
| State: | MA |
| City / Town: | Cambridge |
| Country: | USA |
| Postal Code: | 02139 |
| Exchange: | NGS |
| CEO: | G. Andre Turenne |
| Employees: | 123 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Voyager gets $165 million upfront + up to $1.7 billion in potential milestone payments
$69 million upfront + up to $155 million in preclinical and Phase 1 options + up to $895 million in developmental milestones.
Voyager Therapeutics is developing targeted gene therapies for severe neurological diseases.
Voyager Therapeutics Inc is functional in the United States biotechnology industry. Its focus lies in the research and development of gene therapies for the cure of severe diseases of the central nervous system such as the Parkinson's, Huntington's and Alzheimer's disease. The company has developed products such as VY-AADC01 for Advanced Parkinson's Disease, VY-HTT01 for Huntington's Disease. Voyager's sole source of revenue is generated through its collaboration with a company called Genzyme. Genzyme funds the collaboration for the multiple gene therapy programs, including programs for Parkinson's disease, Friedreich's ataxia, and Huntington's disease, as well as other CNS disorders.
| Website: | www.voyagertherapeutics.com |
| Email: | mosborne@vygr.com |
| Main Phone: | +1 857 259-5340 |
| Address: | 75 Sidney Street |
| State: | MA |
| City / Town: | Cambridge |
| Country: | USA |
| Postal Code: | 02139 |
| Exchange: | NGS |
| CEO: | G. Andre Turenne |
| Employees: | 123 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Voyager gets $165 million upfront + up to $1.7 billion in potential milestone payments
$69 million upfront + up to $155 million in preclinical and Phase 1 options + up to $895 million in developmental milestones.
Voyager Therapeutics is developing targeted gene therapies for severe neurological diseases.
| Last Price 12.82 | Change $ -0.03 | Change % -0.23 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 12.85 | High 12.92 | Low 12.31 | Prev Close 12.85 |
| Last Trade | Volume 315,171 | 52 Wk Hi 28.79 | 52 Wk Low 7.76 |
| Market Cap 475.3 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 37,073,347.00 | EPS (TTM) -1.62 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 9 | 23 |
| Number of Buys | 4 | 4 |
| Number of Sells | 5 | 19 |
| Net Activity | -2451 | -86149 |
| Last 10 Buys | Shares |
|---|---|
| Steven M. Paul | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Bernard Ravina | 1,000 |
| Jane Pritchett Henderson | 1,000 |
| Jane Pritchett Henderson | 1,000 |
| Jane Pritchett Henderson | 1,000 |
| Jane Pritchett Henderson | 1,000 |
| Bernard Ravina | 1,000 |
| Dinah Sah | 1,000 |
| Bernard Ravina | 1,000 |
| Bernard Ravina | 1,000 |
| Bernard Ravina | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 43 | 43 | 43 | 43 |
| Low Target Price Estimate | 17 | 17 | 17 | 17 |
| Mean Target Price Estimate | 32.22 | 32.5 | 32.5 | 32.22 |
| Standard Deviation | 7.36 | 7.82 | 7.82 | 7.36 |
| Date of Most Recent Estimate | 06/04/18 | 05/16/18 | 05/16/18 | 06/04/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-06-15 |
| 3 | Initial statement of beneficial ownership of securities | 2 | 2018-06-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 11 | 2018-06-05 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-29 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 106 | 2018-05-10 |
| 8-K | Report of unscheduled material events or corporate changes. | 9 | 2018-05-10 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 34 | 2018-04-27 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-12 |
| CT ORDER | 1 | 2018-04-05 | |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-03-26 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 3 | 3 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.5 | 1.5 | 1.63 | 1.63 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait